Zymeworks Inc. presented six posters ... market conditions; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and ...

Presented new preclinical data for OP-3136 at the American Association for Cancer Research (AACR) Annual Meeting in April, demonstrating anti-tumor activity in pre-clinical in vitro and in vivo ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human ...

Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash ...

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, ...

Secured first revenue-generating contract for ECO SynthesisTM manufacturing services Company reiterates full-year financial guidance <p ...

Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines ...

Bally’s Corporation (NYSE: BALY) announced today that it will release its financial results for the first quarter ended March 31, 2025 after the market ... our authors to report on investments ...